FDA confirms CardiAMP HF II trial may support premarket approval for heart failure therapy

BioCardia received FDA confirmation that its ongoing CardiAMP Heart Failure II trial may support premarket approval for its cell therapy treating ischemic heart failure. The positive FDA feedback potentially clears a major regulatory hurdle for a therapy targeting over one million U.S. patients.